184 related articles for article (PubMed ID: 34293398)
1. Pan-cancer analysis reveals that neurotrophin signaling correlates positively with anti-tumor immunity, clinical outcomes, and response to targeted therapies and immunotherapies in cancer.
Feng Q; Song D; Wang X
Life Sci; 2021 Oct; 282():119848. PubMed ID: 34293398
[TBL] [Abstract][Full Text] [Related]
2. The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer.
Chen Z; Chen C; Li L; Zhang T; Wang X
Comput Struct Biotechnol J; 2021; 19():5428-5442. PubMed ID: 34667536
[TBL] [Abstract][Full Text] [Related]
3.
Li M; Ma Y; Zhong Y; Liu Q; Chen C; Qiang L; Wang X
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037113
[TBL] [Abstract][Full Text] [Related]
4. Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
Jiang Z; Liu Z; Li M; Chen C; Wang X
EBioMedicine; 2019 Apr; 42():431-442. PubMed ID: 30935888
[TBL] [Abstract][Full Text] [Related]
5. Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.
Zeng P; Zhang X; Xiang T; Ling Z; Lin C; Diao H
Bioengineered; 2022 Feb; 13(2):3221-3239. PubMed ID: 35067176
[TBL] [Abstract][Full Text] [Related]
6. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors.
Siemers NO; Holloway JL; Chang H; Chasalow SD; Ross-MacDonald PB; Voliva CF; Szustakowski JD
PLoS One; 2017; 12(7):e0179726. PubMed ID: 28749946
[TBL] [Abstract][Full Text] [Related]
8. Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma.
Liu Q; Nie R; Li M; Li L; Zhou H; Lu H; Wang X
Comput Struct Biotechnol J; 2021; 19():4472-4485. PubMed ID: 34471493
[TBL] [Abstract][Full Text] [Related]
9. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
10. HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers.
Chen B; Li L; Li M; Wang X
Cell Oncol (Dordr); 2020 Oct; 43(5):877-888. PubMed ID: 32488852
[TBL] [Abstract][Full Text] [Related]
11. Integrative bioinformatics analysis of WDHD1: a potential biomarker for pan-cancer prognosis, diagnosis, and immunotherapy.
Cui Z; Zou F; Wang R; Wang L; Cheng F; Wang L; Pan R; Guan X; Zheng N; Wang W
World J Surg Oncol; 2023 Sep; 21(1):309. PubMed ID: 37759234
[TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect.
Han X; Ye J; Huang R; Li Y; Liu J; Meng T; Song D
Front Immunol; 2022; 13():900273. PubMed ID: 36159856
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy.
Li B; Severson E; Pignon JC; Zhao H; Li T; Novak J; Jiang P; Shen H; Aster JC; Rodig S; Signoretti S; Liu JS; Liu XS
Genome Biol; 2016 Aug; 17(1):174. PubMed ID: 27549193
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy.
Xie F; Zhang J; Wang J; Reuben A; Xu W; Yi X; Varn FS; Ye Y; Cheng J; Yu M; Wang Y; Liu Y; Xie M; Du P; Ma K; Ma X; Zhou P; Yang S; Chen Y; Wang G; Xia X; Liao Z; Heymach JV; Wistuba II; Futreal PA; Ye K; Cheng C; Xia T
Clin Cancer Res; 2020 Jun; 26(12):2908-2920. PubMed ID: 31911545
[TBL] [Abstract][Full Text] [Related]
15. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
16. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
17. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
18. Pan-Cancer Analysis Reveals That
Chen Z; Chen C; Li L; Zhang T; Wang X
Front Cell Dev Biol; 2021; 9():729927. PubMed ID: 34616736
[No Abstract] [Full Text] [Related]
19. TRPV1 Is a Potential Tumor Suppressor for Its Negative Association with Tumor Proliferation and Positive Association with Antitumor Immune Responses in Pan-Cancer.
Nie R; Liu Q; Wang X
J Oncol; 2022; 2022():6964550. PubMed ID: 36304985
[TBL] [Abstract][Full Text] [Related]
20. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
